KR100765579B1 - 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도 - Google Patents

제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도 Download PDF

Info

Publication number
KR100765579B1
KR100765579B1 KR1020027007332A KR20027007332A KR100765579B1 KR 100765579 B1 KR100765579 B1 KR 100765579B1 KR 1020027007332 A KR1020027007332 A KR 1020027007332A KR 20027007332 A KR20027007332 A KR 20027007332A KR 100765579 B1 KR100765579 B1 KR 100765579B1
Authority
KR
South Korea
Prior art keywords
receptor
antagonists
agent
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027007332A
Other languages
English (en)
Korean (ko)
Other versions
KR20030016208A (ko
Inventor
스티븐 안토니 빌스테인
피터 두모빅
니콜라 프랑코
마크 토마스 이비키
한스-위르겐 판쿠헤
에드워드 죠셉 쥬니어 윌루즈
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030016208A publication Critical patent/KR20030016208A/ko
Application granted granted Critical
Publication of KR100765579B1 publication Critical patent/KR100765579B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020027007332A 1999-12-10 2000-12-08 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도 Expired - Fee Related KR100765579B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10
US09/458,388 1999-12-10
PCT/EP2000/012420 WO2001041748A2 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
KR20030016208A KR20030016208A (ko) 2003-02-26
KR100765579B1 true KR100765579B1 (ko) 2007-10-09

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027007332A Expired - Fee Related KR100765579B1 (ko) 1999-12-10 2000-12-08 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도

Country Status (30)

Country Link
EP (3) EP1286668B1 (https=)
JP (1) JP2003523324A (https=)
KR (1) KR100765579B1 (https=)
CN (2) CN1875966A (https=)
AR (1) AR026916A1 (https=)
AT (1) ATE293971T1 (https=)
AU (2) AU778869B2 (https=)
BR (1) BR0016275A (https=)
CA (1) CA2388959A1 (https=)
CO (1) CO5261535A1 (https=)
CZ (1) CZ300690B6 (https=)
DE (1) DE60019814T2 (https=)
DK (1) DK1286668T3 (https=)
ES (1) ES2240229T3 (https=)
HU (1) HUP0301122A3 (https=)
IL (2) IL149496A0 (https=)
MX (1) MXPA02005695A (https=)
MY (1) MY133423A (https=)
NO (1) NO20022680L (https=)
NZ (2) NZ531489A (https=)
PE (1) PE20011030A1 (https=)
PL (1) PL202201B1 (https=)
PT (1) PT1286668E (https=)
RU (1) RU2264215C2 (https=)
SG (1) SG152025A1 (https=)
SK (1) SK8062002A3 (https=)
TR (1) TR200402293T2 (https=)
TW (1) TWI263496B (https=)
WO (1) WO2001041748A2 (https=)
ZA (1) ZA200204493B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261606A1 (en) * 2000-05-18 2001-11-26 Glaxo Group Limited Method for treating functional dyspepsia
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
JP2006528231A (ja) * 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
RU2007105346A (ru) * 2004-07-14 2008-09-27 Новартис АГ (CH) Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
MX2007009136A (es) * 2005-01-31 2007-09-06 Novartis Ag Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones.
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
RU2008152196A (ru) * 2006-06-15 2010-07-20 Новартис АГ (CH) Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505322A1 (en) 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
EP0617620B1 (en) * 1991-12-21 1998-09-09 Smithkline Beecham Plc Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
DK0794184T3 (da) * 1994-11-21 2001-07-30 Dainippon Pharmaceutical Co 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505322A1 (en) 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines

Also Published As

Publication number Publication date
SG152025A1 (en) 2009-05-29
AU2005200797A1 (en) 2005-03-17
AU2672801A (en) 2001-06-18
TWI263496B (en) 2006-10-11
HUP0301122A2 (hu) 2003-08-28
NZ566800A (en) 2009-11-27
HUP0301122A3 (en) 2005-03-29
CN1409634A (zh) 2003-04-09
CZ20021967A3 (cs) 2002-08-14
TR200402293T2 (tr) 2004-10-21
CN1875966A (zh) 2006-12-13
MXPA02005695A (es) 2002-09-18
NO20022680L (no) 2002-08-12
NZ531489A (en) 2005-09-30
PE20011030A1 (es) 2001-10-31
SK8062002A3 (en) 2003-04-01
PL202201B1 (pl) 2009-06-30
PL355663A1 (en) 2004-05-04
DE60019814D1 (de) 2005-06-02
EP1488788A1 (en) 2004-12-22
CA2388959A1 (en) 2001-06-14
CO5261535A1 (es) 2003-03-31
EP1286668B1 (en) 2005-04-27
DK1286668T3 (da) 2005-08-15
RU2264215C2 (ru) 2005-11-20
ATE293971T1 (de) 2005-05-15
WO2001041748A2 (en) 2001-06-14
IL149496A0 (en) 2002-11-10
JP2003523324A (ja) 2003-08-05
AR026916A1 (es) 2003-03-05
WO2001041748A3 (en) 2002-12-19
NO20022680D0 (no) 2002-06-06
BR0016275A (pt) 2002-08-27
CN1310644C (zh) 2007-04-18
KR20030016208A (ko) 2003-02-26
RU2002118316A (ru) 2004-02-20
ZA200204493B (en) 2003-09-29
ES2240229T3 (es) 2005-10-16
AU778869B2 (en) 2004-12-23
IL149496A (en) 2009-12-24
PT1286668E (pt) 2005-08-31
AU2005200797B2 (en) 2008-01-24
MY133423A (en) 2007-11-30
EP1286668A2 (en) 2003-03-05
DE60019814T2 (de) 2006-03-02
CZ300690B6 (cs) 2009-07-15
EP1913944A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
KR100765579B1 (ko) 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도
US20040092511A1 (en) Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
EP1789067B1 (en) Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
JP2008506651A (ja) Ｄｐｐ−ｉｖ阻害剤と５−ｈｔ３および／または５−ｈｔ４受容体を調節する化合物の組合せ剤
KR101331754B1 (ko) Ｇｉ (특히 ｇｅｒｄ)에서의 ｍｇｌｕｒ5 (특히ａｆｑ056)의 용도
JP2009520726A (ja) ５−ｈｔ４アゴニストおよびコリンエステラーゼ阻害剤の組合せ剤
KR20100102157A (ko) 이파몰레린을 이용하여 위장관계 운동성을 촉진시키는 방법
KR20150036115A (ko) 위식도 역류증에 대한 약제
HK1053266A1 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
HK1053266B (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
HK1105279B (en) Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20101001

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111003

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111003

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000